Skip to main content

Table 1 Baseline characteristics of the participants

From: Effects of early estradiol valerate administration on bone turnover markers in surgically induced menopausal women

 

Hormone treatment group (n = 21)

No treatment group (n = 20)

p-value

Age* (years)

47.14 (4.1)

49.35 (2.7)

0.049

Age < 45 years

5 (24%)

0 (0%)

 

Age ≥ 45 years

16 (76%)

20 (100%)

 

BMI* (kg/m2)

26.40 (4.9)

23.96 (2.5)

0.056

Marital status

Married

17 (81%)

15 (75%)

 

Single

4 (19%)

5 (25%)

 

Parity

Nulliparous

9 (43%)

9 (45%)

 

Multiparous

12 (57%)

11 (55%)

 

Underlying disease

Hypertension

2 (9%)

3 (15%)

 

Dyslipidemia

1 (5%)

1 (5%)

 

Primary indication for surgery

Myoma uteri

6 (29%)

11 (55%)

 

Adenomyosis

4(19%)

6 (30%)

 

Endometriosis, endometrioma

10(48%)

4 (20%)

 

BRCA mutation

0

1 (5%)

 

Endometrial hyperplasia

0

1 (5%)

 

CIN III

1 (5%)

0

 

FSH** (IU/L)

10.59 (6.84–36.64)

11.86 (4.81–28.30)

0.735

CTX** (ng/ml)

0.21 (0.17–0.35)

0.24 (0.19–0.34)

0.273

P1NP** (ng/ml)

37.97 (26.09–54.62)

42.11 (35.26–72.57)

0.112

  1. *Data was presented as mean (SD)
  2. **Data was presented as median (IQR)